BioLASCO Taiwan Co., Ltd.

6662

TW0006662000

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
36.2 ^TWD	+1.26%		+3.58%	+9.04%

May. 14	BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 20	BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

BioLASCO Taiwan Co., Ltd. Announces CEO Changes

November 05, 2021 at 05:13 am EDT

BioLASCO Taiwan Co., Ltd. announced appointment of Chen, Yung-Hao as president of the company in place of Chen, Cheng-Chung, effective January 1, 2022.

Latest news about BioLASCO Taiwan Co., Ltd.

BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
BioLASCO Taiwan Co., Ltd. Announces Cash Dividend	23-07-31	CI
BioLASCO Taiwan Co., Ltd. Announces Change of Remuneration Committee	23-06-12	CI
BioLASCO Taiwan Co., Ltd. Announces Change of Audit Committee	23-06-12	CI
BioLASCO Taiwan Co., Ltd. Announces Board Changes	23-06-12	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-04	CI
BioLASCO Taiwan Co., Ltd. Announces Cash Dividend, Payable on August 26, 2022	22-07-05	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-04	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-23	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-05	CI
BioLASCO Taiwan Co., Ltd. Announces CEO Changes	21-11-05	CI
Biolasco Taiwan Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-05	CI
BioLASCO Taiwan Co., Ltd. Announces Cash Dividend, Payable on September 22, 2021	21-08-05	CI
BioLASCO Taiwan Co., Ltd. Elects Liu, Wei-Ming as Natural-Person Director	21-08-05	CI
Biolasco Taiwan Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-25	CI
BioLASCO Taiwan Co., Ltd. Appoints Stacey Yu as Corporate Governance Officer	21-03-25	CI
BioLASCO Taiwan Co., Ltd. Renews Ten-Year Distribution and Propagation Agreement with Charles River Laboratories International, Inc	21-03-18	CI
BioLASCO Taiwan Co., Ltd. Announces Resignation of Chen,Chien-Chang as Director	21-03-03	CI
Biolasco Taiwan Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-11	CI

Chart BioLASCO Taiwan Co., Ltd.

Duration

Period

More charts

BioLASCO Taiwan Co., Ltd. is a Taiwan-based company mainly engaged in the production of Specific Pathogen Free (SPF) laboratory animals and the high-value special-mode experimental animals, as well as the introduction and production of highly-applicable disease-mode animals. The company also provides equipment related to feeding, supplies and testing platform, life science research and pharmaceutical development services.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOLASCO TAIWAN CO., LTD.	+9.04%	28.51M
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B